ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
Sidoni
Angelo
A
Cartaginese
Fabio
F
Colozza
Mariantonietta
M
Gori
Stefania
S
Crinó
Lucio
L
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy; D002277:Carcinoma / Q000737:chemistry* / Q000188:drug therapy; D004268:DNA-Binding Proteins / Q000032:analysis*; D004720:Endonucleases / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D018579:Patient Selection; D017671:Platinum Compounds / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D004720:Endonucleases; D017671:Platinum Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human; C071447:ERCC1 protein, human